Gene expression in midgut carcinoid tumors: Potential targets for immunotherapy

Acta Oncologica

Volumn 44, Issue 1, 2005, Pages 32-40

  Vikman, Sofia ^a   Essand, Magnus ^a   Cunningham, Janet L ^b   De La Torre, Manuel ^a   Öberg, Kjell ^b   Tötterman, Thomas H ^a   Giandomenico, Valeria ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN IA 2; TRANSCRIPTION FACTOR CDX2; TRYPTOPHAN HYDROXYLASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 1;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOID; DRUG TARGETING; ENTEROCHROMAFFIN CELL; GENE EXPRESSION; GENE OVEREXPRESSION; HORMONE RELEASE; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MIDGUT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BIOPSY, NEEDLE; CARCINOID TUMOR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY;

EID: 13844271995     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510007404     Document Type: Article

References (44)

1. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002;14:38-45.
2. Oberg K. Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 2003;3:863-77.
3. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumors (including bronchopulmonary and thymic neoplasms), Part I: General overview. Acta Oncologica 2004;43:617-25.
4. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumors (including bronchopulmonary and thymic neoplasms), Part II: Specific NE tumour types. Acta Oncologica 2004;43:626-36.
5. Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22-32.
6. Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
7. Parmiani G, Sensi M, Castelli C, et al. T-cell response to unique and shared antigens and vaccination of cancer patients. Cancer Immun 2002;2:6.
8. Paczesny S, Banchereau J, Wittkowski KM, et al. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med 2004;199:1503-11.
9. Wessig C, Klein R, Schneider MF, et al. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003;61:195-8.
10. Evergren E, Marcucci M, Tomilin N, et al. Amphiphysin is a component of clathrin coats formed during synaptic vesicle recycling at the lamprey giant synapse. Traffic 2004;5:514-28.
11. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an 'on/off' switch controlling dense-core secretory granule biogenesis. Cell 2001;106:499-509.
12. Cunningham JL, Lopez-Egido JR, Janson ET, et al. Transmembrane protein tyrosine phosphatase IA-2 (ICA512) is expressed in human midgut carcinoids but is not detectable in normal enterochromaffin cells. J Endocrinol 2000;164:315-22.
13. Andersen JN, Jansen PG, Echwald SM, et al. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. Faseb J 2004;18:8-30.
14. Caballero OL, Resto V, Patturajan M, et al. Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1). Oncogene 2002;21:3003-10.
15. Valtorta F, Pennuto M, Bonanomi D, Benfenati F. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis? Bioessays 2004;26:445-53.
16. Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003;299:76.
17. Erickson JD, Schafer MK, Bonner TI, et al. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996;93:5166-71.
18. Jakobsen AM, Andersson P, Saglik G, et al. Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours. J Pathol 2001;195:463-72.
19. Moskaluk CA, Zhang H, Powell SM, et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-9.
20. Ozaki Y, Kontani K, Hanaoka J, et al. Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Cancer 2002;95:1954-62.
21. Ozaki Y, Kontani K, Teramoto K, et al. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy. Biochem Biophys Res Commun 2004;317:1089-95.
22. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309-17.
23. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int J Mol Med 2002;9:401-4.
24. Takada M, Koizumi T, Toyama H, et al. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology 2001;48:1577-8.
25. Hsieh HL, Schafer BW, Sasaki N, Heizmann CW. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 2003;307:375-81.
26. Shichijo S, Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998;187:277-88.
27. Casati C, Dalerba P, Rivoltini L, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 2003;63:4507-15.
28. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004;2:19.
29. Mangino G, Grazia Capri M, Barnaba V, Alberti S. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells. Int J Cancer 2002;101:353-9.
30. De Backer O, Arden KC, Boretti M, et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 1999;59:3157-65.
31. Kobayashi Y, Higashi T, Nouso K, et al. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J Hepatol 2000;32:612-7.
32. Odunsi K, Jungbluth AA, Stocken E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003;63:6076-83.
33. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003;194:272-88.
34. Haffner AC, Tassis A, Zepter K, et al. Expression of cancer/testis antigens in cutaneous T cell lymphomas. Int J Cancer 2002;97:668-70.
35. Preuss KD, Zwick C, Bormann C, et al. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002;188:43-50.
36. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
37. Schott M, Seissler J. Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies. Trends Endocrinol Metab 2003;14:156-62.
38. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-5.
39. Ekwall O, Hedstrand H, Grimelius L, et al. Identification of tryptophan hydroxylase as an intestinal autoantigen. Lancet 1998;352:279-83.
40. Erickson JD, Varoqui H. Molecular analysis of vesicular amine transporter function and targeting to secretory organelles. Faseb J 2000;14:2450-8.
41. Eiden LE, Schafer MK, Weihe E, Schutz B. The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch 2004;447:636-40.
42. Dromey JA, Weenink SM, Peters GH, et al. Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. J Immunol 2004;172:4084-90.
43. Parekh D, Ishizuka J, Townsend CM Jr, et al. Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas 1994;9:83-90.
44. Tran VS, Marion-Audibert AM, Karatekin E, et al. Serotonin secretion by human carcinoid BON cells. Ann NY Acad Sci 2004;1014:179-88.